Connect your AI

DBV Technologies DBVT Other Working Capital

Other Working Capital at other companies

Kymera TherapeuticsKYMR

-$2.15M-410%

IncyteINCY

-$12.77M-141%

Other financials

Income statement

Revenue$900.0K+12.5%

Operating income-$47.9M-80.1%

Net income-$47.6M-75.6%

EPS (diluted)-$0.11+57.7%

Balance sheet

Cash & equivalents$229.2M+1,668%

Total debt$6.1M-15.7%

Total equity$207.9M+7,069%

Total assets$266.4M+427%

Cash flow

Operating cash flow-$49.1M-149%

CapEx$400.0K—

Free cash flow-$49.5M-151%

Valuation

Market cap$923.31M+269%

Enterprise value$700.21M+188%

P/S159.6×+89.0×

Profitability

Operating margin-2,910.4%-265pp

Net margin-2,895.4%-257pp

FCF margin-2,619.5%+69.9pp

Returns & leverage

Return on equity-158.9%-26.4pp

Debt / equity0×-2.5×

Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is DBV Technologies's other working capital?: DBV Technologies (DBVT) reported other working capital of $0 in Q1 2026.
How has DBV Technologies's other working capital changed year-over-year?: DBV Technologies's other working capital increased by 100.0% year-over-year, from -$500K to $0.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.